AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21692299 — intervention group
Group type: COMPARATOR
Intervention: Group B (compound general anesthesia with placebo points)
Number of subjects: 90
Study 21692299 — intervention group
Group type: COMPARATOR
Intervention: Group C (general anesthesia only)
Number of subjects: 90
Study 19539097 — intervention group
Group type: COMPARATOR
Intervention: Zoledronate
Number of subjects: 4163
Study 19539097 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 4163
Study 19539097 — intervention group
Group type: COMPARATOR
Intervention: Clodronate
Number of subjects: 4163
Study 19539097 — intervention group
Group type: COMPARATOR
Intervention: Clodronate, pamidronate, and zoledronate
Number of subjects: 4163
Study 16818530 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-loop feedback plus reinforcement
Number of subjects: 30
Study 16818530 — intervention group
Group type: COMPARATOR
Intervention: Open-loop feedback alone (Control)
Number of subjects: 30
Study 12615634 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated 6-minute walk test
Number of subjects: 761
Study 12615634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous (circular or oval) walking course
Number of subjects: 761
Study 12615634 — intervention group
Group type: COMPARATOR
Intervention: Straight (out and back) walking course
Number of subjects: 761
Study 10684705 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-containing chemotherapy
Number of subjects: 53
Study 9373687 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-order stereoscopic motion (higher-order SM) under correlated conditions with long ISI (ISI > 73 msec)
Number of subjects: 0
Study 9373687 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-order stereoscopic motion (higher-order SM) under uncorrelated conditions with zero ISI
Number of subjects: 0
Study 9373687 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-order stereoscopic motion (higher-order SM) with large distance of dot jump or varied directions of dots' motion
Number of subjects: 0
Study 9373687 — intervention group
Group type: EXPERIMENTAL
Intervention: Local first-order motion signals weakened by appropriate temporal and spatial conditions or by incoherent motion directions
Number of subjects: 0
Study 8360132 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg bd
Number of subjects: 662
Study 8360132 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 200 mg for the first dose followed by 100 mg od
Number of subjects: 662
Study 8360132 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 662
Study 8360132 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 662
Study 3739357 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg theophyllinethylendiamine (Euphyllin)
Number of subjects: 20
Study 3739357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medication consisting of 25 mg theophyllin, 85 mg etophyllin, 30 mg papaverine and 0.1 mg atropine methylnitrate (Perphyllon)
Number of subjects: 20
Study 30407744 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free jet (MadaJet)
Number of subjects: 59
Study 30407744 — intervention group
Group type: COMPARATOR
Intervention: Needle injection
Number of subjects: 59
Study 29995326 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI + booster email
Number of subjects: 537
Study 29995326 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI-only
Number of subjects: 537
Study 29995326 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 537
Study 26939115 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 140
Study 26939115 — intervention group
Group type: COMPARATOR
Intervention: Manual SICS
Number of subjects: 140
Study 24702786 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive mental intervention (support, counselling, music, massage plus conventional therapy)
Number of subjects: 120
Study 24702786 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (three‐cavity gastric tube, fasting, parenteral/enteral nutrition, routine care, health guidance)
Number of subjects: 120
Study 24702786 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive mental intervention
Number of subjects: 120
Study 24702786 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 120
Study 22691658 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 60
Study 22691658 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF
Number of subjects: 60
Study 19856237 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured training program in psychotherapeutic skills
Number of subjects: 170
Study 19856237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 170
Study 17658101 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of a placebo medication and preincision local infiltration of 40 mL of 0.5 per cent bupivicaine at trocar sites
Number of subjects: 55
Study 17658101 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of 50 mg of rofecoxib
Number of subjects: 55
Study 17658101 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of 50 mg of rofecoxib and preincision local infiltration of 40 mL of 0.5 per cent bupivicaine
Number of subjects: 55
Study 17658101 — intervention group
Group type: COMPARATOR
Intervention: Preoperative oral administration of a placebo medication
Number of subjects: 55
Study 16061594 — intervention group
Group type: EXPERIMENTAL
Intervention: Infasurf (calfactant)
Number of subjects: 2110
Study 16061594 — intervention group
Group type: COMPARATOR
Intervention: Survanta (beractant)
Number of subjects: 2110
Study 11470697 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 27
Study 11470697 — intervention group
Group type: COMPARATOR
Intervention: timolol gel 0.5%
Number of subjects: 27
Study 10085699 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic neurological examination, conduction velocities in the sural and tibial nerves, R-R interval variation, sympathetic skin response
Number of subjects: 51
Study 10085699 — intervention group
Group type: EXPERIMENTAL
Intervention: R-R interval variation
Number of subjects: 51
Study 10085699 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of nephropathy, duration of renal treatment, duration of dialysis treatment
Number of subjects: 51
Study 7921444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with human recombinant IL-8
Number of subjects: 19
Study 7921444 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 19
Study 2842403 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9
Number of subjects: 818
Study 2842403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study 31748125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1723
Study 28963853 — intervention group
Group type: EXPERIMENTAL
Intervention: LETS ACT (n = 142)
Number of subjects: 263
Study 28963853 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC; n = 121)
Number of subjects: 263
Study 26289723 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week telerehabilitation programme in addition to conventional cardiac rehabilitation
Number of subjects: 140
Study 26289723 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation alone
Number of subjects: 140
Study 24433231 — intervention group
Group type: EXPERIMENTAL
Intervention: I Can Cope (4 sessions: learning about cancer; understanding cancer treatments; relieving cancer pain; keeping well in mind and body)
Number of subjects: 140
Study 24433231 — intervention group
Group type: COMPARATOR
Intervention: Wellness intervention (4 sessions: humor, meditation, relaxation, and music therapy)
Number of subjects: 140
Study 23185761 — intervention group
Group type: EXPERIMENTAL
Intervention: Youdujing (YDJ) external lotion and YDJ cream
Number of subjects: 70
Study 23185761 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 70
Study 23185761 — intervention group
Group type: EXPERIMENTAL
Intervention: Youdujing (YDJ) treatment
Number of subjects: 70
Study 20473630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribonuclease-enriched lactoferrin (R-ELF) supplementation (2 × 125 mg/day)
Number of subjects: 38
Study 20473630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium supplement only)
Number of subjects: 38
Study 17495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg)
Number of subjects: 15
Study 17495194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16135905 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level intervention
Number of subjects: 1172
Study 16135905 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training workshops
Number of subjects: 1172
Study 16135905 — intervention group
Group type: COMPARATOR
Intervention: Education-only delayed control intervention
Number of subjects: 1172
Study 11753129 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate
Number of subjects: 0
Study 11753129 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prostatectomy
Number of subjects: 0
Study 11753129 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative finasteride
Number of subjects: 0
Study 11753129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Number of subjects: 0
Study 11753129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder infusion prior to catheter removal
Number of subjects: 0
Study 11753129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol‐glycine in assessment of the absorption of irrigation fluid
Number of subjects: 0
Study 11069268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 20
Study 11069268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 20
Study 11069268 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched normal-control subjects)
Number of subjects: 20
Study 8839904 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecogalan sodium (dosage levels: 125, 185, 240, 300, 390, 445, and 500 mg/m2) administered via single i.v. infusion every three weeks for 1 to 24 hours.
Number of subjects: 33
Study 8839904 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecogalan sodium at the recommended phase II dose of 390 mg/m2 over 24 hours.
Number of subjects: 33
Study 1602944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (93% of total caloric intake as carbohydrate) after glycogen-depletion protocol
Number of subjects: 14
Study 1602944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (23% of total caloric intake as carbohydrate) after glycogen-depletion protocol
Number of subjects: 14
Study 1602944 — intervention group
Group type: COMPARATOR
Intervention: Recorded ad libitum dietary consumption
Number of subjects: 14
Study 1602944 — intervention group
Group type: COMPARATOR
Intervention: Control condition (ad libitum diet)
Number of subjects: 14
Study 6386932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amrinone (113 +/- 33 mg three times daily)
Number of subjects: 173
Study 6386932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amrinone
Number of subjects: 173
Study 6386932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 6386932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amrinone and Placebo
Number of subjects: 173
Study 31279306 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific regimen not detailed)
Number of subjects: 0
Study 31279306 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (in PENELOPE validation cohort)
Number of subjects: 0
Study 31279306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-chemotherapy (in AURELIA validation cohort)
Number of subjects: 0
Study 29228160 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive plus usual care (n=5398 mother-infant dyads)
Number of subjects: 10010
Study 29228160 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n=4612 mother-infant dyads)
Number of subjects: 10010
Study 29228160 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive plus usual care
Number of subjects: 10010
Study 29228160 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 10010
Study 26717304 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC print ads with disease information
Number of subjects: 4064
Study 26717304 — intervention group
Group type: COMPARATOR
Intervention: DTC print ads without disease information
Number of subjects: 4064
Study 24818986 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical websites
Number of subjects: 52
Study 24818986 — intervention group
Group type: COMPARATOR
Intervention: General health and wellness control websites
Number of subjects: 52
Study 22472523 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (MI)
Number of subjects: 162
Study 22472523 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (BA)
Number of subjects: 162
Study 20305926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 19
Study 20305926 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 17985505 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking an extra 30 minutes per day
Number of subjects: 19
Study 17985505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no walking advice)
Number of subjects: 19
Study 16306520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg three times daily)
Number of subjects: 182
Study 16306520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 16306520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 182
Study 11263599 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 8943
Study 11263599 — intervention group
Group type: COMPARATOR
Intervention: Hirudin
Number of subjects: 8943
Study 11263599 — intervention group
Group type: COMPARATOR
Intervention: No (re)MI
Number of subjects: 8943
Study 9268808 — intervention group
Group type: EXPERIMENTAL
Intervention: English-speaking group
Number of subjects: 0
Study 9268808 — intervention group
Group type: COMPARATOR
Intervention: Spanish-speaking group
Number of subjects: 0
Study 8331205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate immediate-release (CT) tablets (2 x 20 mg)
Number of subjects: 12
Study 8331205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam sustained-release (SR) tablets (2 x 30 mg)
Number of subjects: 12
Study 8331205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3570035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 7
Study 3570035 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 7
Study 3570035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 7
Study 3570035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 7
Study 2598862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone lid method
Number of subjects: 60
Study 2598862 — intervention group
Group type: COMPARATOR
Intervention: Conservative procedure
Number of subjects: 60
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation (n = 51)
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain >7g/d during follow-up (n = 14)
Number of subjects: 102
Study 31544802 — intervention group
Group type: COMPARATOR
Intervention: Weight gain <7g/d
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (28 children improved BMI-SDS)
Number of subjects: 102
Study 31544802 — intervention group
Group type: COMPARATOR
Intervention: Group B (23 children did not improve BMI-SDS)
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with lower Ht-SDS before NR
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear growth velocity after NR
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 102
Study 28363880 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CPD program on providing oral hygiene care to stroke patients using TPB
Number of subjects: 547
Study 28363880 — intervention group
Group type: COMPARATOR
Intervention: Web-based CPD program not specific to oral hygiene
Number of subjects: 547
Study 26497942 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed informed consent process in neonatal research
Number of subjects: 0
Study 26497942 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical investigations on parental perspectives
Number of subjects: 0
Study 26497942 — intervention group
Group type: EXPERIMENTAL
Intervention: Large randomized controlled multicenter trials
Number of subjects: 0
Study 26497942 — intervention group
Group type: EXPERIMENTAL
Intervention: Current funding and regulation of research
Number of subjects: 0
Study 23182947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 50
Study 23182947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 50
Study 23182947 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 50
Study 21709083 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Number of subjects: 40
Study 21709083 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg
Number of subjects: 40
Study 21709083 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 40
Study 21709083 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg vs 600 mg
Number of subjects: 40
Study 18249500 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 22982
Study 16854197 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic Plate (OP)
Number of subjects: 0
Study 16854197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OP)
Number of subjects: 0
Study 15809819 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus nesiritide
Number of subjects: 900
Study 15809819 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus placebo
Number of subjects: 900
Study 11179831 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant MPO genotype
Number of subjects: 0
Study 11179831 — intervention group
Group type: COMPARATOR
Intervention: Wild-type MPO genotype
Number of subjects: 0
Study 9024742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 22
Study 9024742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8298540 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive psychotherapy
Number of subjects: 220
Study 8298540 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory psychotherapy
Number of subjects: 220
Study 8298540 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive therapy
Number of subjects: 220
Study 8298540 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory therapy
Number of subjects: 220
Study 8298540 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 220
Study 3552841 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) treatment
Number of subjects: 433
Study 3552841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 433
Study 31010364 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular body build with muscle-encouraging messages
Number of subjects: 508
Study 31010364 — intervention group
Group type: COMPARATOR
Intervention: Muscular body build with muscle-discouraging messages
Number of subjects: 508
Study 31010364 — intervention group
Group type: COMPARATOR
Intervention: Average body build
Number of subjects: 508
Study 31010364 — intervention group
Group type: COMPARATOR
Intervention: Overweight body build
Number of subjects: 508
Study 28342632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor (90mg loading dose, then 90mg daily)
Number of subjects: 52
Study 28342632 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ticagrelor (180mg loading dose, then 90mg twice daily)
Number of subjects: 52
Study 28342632 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300mg loading dose, then 75mg daily)
Number of subjects: 52
Study 25620535 — intervention group
Group type: EXPERIMENTAL
Intervention: Etifoxine 150 mg/day for 28 days
Number of subjects: 202
Study 25620535 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 1.5 mg/day for 28 days
Number of subjects: 202
Study 25620535 — intervention group
Group type: EXPERIMENTAL
Intervention: Etifoxine
Number of subjects: 202
Study 25620535 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam
Number of subjects: 202
Study 23421900 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler training (verbal training, demonstration movie, and leaflet)
Number of subjects: 69
Study 23421900 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhaler training)
Number of subjects: 69
Study 21375356 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 72
Study 19067864 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (from twice daily to one application every other day) combined with the studied cream (twice daily)
Number of subjects: 86
Study 19067864 — intervention group
Group type: EXPERIMENTAL
Intervention: Studied cream (twice daily)
Number of subjects: 86
Study 19067864 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (once or twice daily)
Number of subjects: 86
Study 16598851 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 9
Study 16598851 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 9